Literature DB >> 9165656

Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications.

J E Nestler1.   

Abstract

The polycystic ovary syndrome (PCOS) is a prevalent disorder affecting approximately 6% of women of reproductive age, and is characterized by anovulation and hyperandrogenism. It has also become apparent that a frequent feature of women with PCOS is insulin resistance accompanied by compensatory hyperinsulinemia, and increasing evidence suggests that hyperinsulinemia plays an important role in the pathogenesis of PCOS. This article will review (1) evidence indicating that insulin contributes to the hyperandrogenism of PCOS by stimulating ovarian androgen production and decreasing serum sex hormone-binding globulin (SHBG) concentrations; (2) possible direct effects of hyperinsulinemia on folliculogenesis; (3) the relationship between insulin and adrenal androgens in women; and (4) therapeutic and clinical implications of these findings.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9165656     DOI: 10.1055/s-2007-1016294

Source DB:  PubMed          Journal:  Semin Reprod Endocrinol        ISSN: 0734-8630


  29 in total

1.  Insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome.

Authors:  Kai I Cheang; Jean-Patrice Baillargeon; Paulina A Essah; Richard E Ostlund; Teimuraz Apridonize; Leila Islam; John E Nestler
Journal:  Metabolism       Date:  2008-10       Impact factor: 8.694

Review 2.  Conserved insulin signaling in the regulation of oocyte growth, development, and maturation.

Authors:  Debabrata Das; Swathi Arur
Journal:  Mol Reprod Dev       Date:  2017-04-24       Impact factor: 2.609

3.  Long-term effect of metformin on metabolic parameters in the polycystic ovary syndrome.

Authors:  Kai I Cheang; Jessica M Huszar; Al M Best; Susmeeta Sharma; Paulina A Essah; John E Nestler
Journal:  Diab Vasc Dis Res       Date:  2009-04       Impact factor: 3.291

4.  Protein modification as oxidative stress marker in follicular fluid from women with polycystic ovary syndrome: the effect of inositol and metformin.

Authors:  P Piomboni; R Focarelli; A Capaldo; A Stendardi; V Cappelli; A Cianci; A La Marca; A Luddi; V De Leo
Journal:  J Assist Reprod Genet       Date:  2014-08-12       Impact factor: 3.412

5.  The effects of old, new and emerging medicines on metabolic aberrations in PCOS.

Authors:  Alexandra Bargiota; Evanthia Diamanti-Kandarakis
Journal:  Ther Adv Endocrinol Metab       Date:  2012-02       Impact factor: 3.565

6.  Insulin resistance in the sisters of women with polycystic ovary syndrome: association with hyperandrogenemia rather than menstrual irregularity.

Authors:  Richard S Legro; Rhonda Bentley-Lewis; Deborah Driscoll; Steve C Wang; Andrea Dunaif
Journal:  J Clin Endocrinol Metab       Date:  2002-05       Impact factor: 5.958

7.  Brothers of women with polycystic ovary syndrome are characterised by impaired glucose tolerance, reduced insulin sensitivity and related metabolic defects.

Authors:  J-P Baillargeon; A C Carpentier
Journal:  Diabetologia       Date:  2007-09-27       Impact factor: 10.122

8.  An internet-based prospective study of body size and time-to-pregnancy.

Authors:  Lauren A Wise; Kenneth J Rothman; Ellen M Mikkelsen; Henrik Toft Sørensen; Anders Riis; Elizabeth E Hatch
Journal:  Hum Reprod       Date:  2009-10-14       Impact factor: 6.918

9.  Pioglitazone Therapy Increases Insulin-Stimulated Release of d-Chiro-Inositol-Containing Inositolphosphoglycan Mediator in Women with Polycystic Ovary Syndrome.

Authors:  Anshu Gupta; Daniela Jakubowicz; John E Nestler
Journal:  Metab Syndr Relat Disord       Date:  2016-03-30       Impact factor: 1.894

10.  Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolism.

Authors:  Jean-Patrice Baillargeon; John E Nestler; Richard E Ostlund; Teimuraz Apridonidze; Evanthia Diamanti-Kandarakis
Journal:  Hum Reprod       Date:  2008-03-29       Impact factor: 6.918

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.